職名 教授
氏名
井上 貴博
生年月  
所属 部局 医学系研究科
学科・専攻 生命医科学専攻
講座 臨床医学系講座
教育研究分野  
TEL  
FAX  
E-mail tinoue28@med.mie-u.ac.jp
個人のホームページ  
学歴 2002.4.-2006.3: 京都大学大学院医学研究科外科系専攻泌尿器科
1994.3: 京都大学医学部卒業
学位 2007.5.23 医学博士号(医博第3124号, 甲第13283号)取得(京都大学)
所属学会 日本泌尿器科学会、日本癌学会、日本癌治療学会、日本泌尿器内視鏡学会、米国泌尿器科学会、米国臨床腫瘍学会、日本内視鏡外科学会、日本VR医学会、日本ロボット外科学会、欧州泌尿器科学会、日本泌尿器腫瘍学会
社会活動 2012年版 前立腺癌診療ガイドライン 編集委員
2016年版 前立腺癌診療ガイドライン 編集委員
2015年1月~2017年9月 泌尿器科紀要編集次長
2016年1月~ 内視鏡外科学会雑誌 編集員
2016年6月~2019年12月 京都市前立腺がん検診委員会 委員
2017年1月~ 日本がん治療認定医機構 教育委員会協力員
2017年4月~ Asian Journal of Endoscopic Surgery Task forceメンバー
2017年4月~ Uro-Lo 企画委員
2017年4月~ 泌尿器科分子・細胞研究会 評議委員
2017年4月~ (公財)前立腺研究財団 プログラム委員
2018年7月~~2020年1月 International Journal of Clinical Oncology Chief Deputy Editor
2019年1月~ 日本癌学会 評議員
2019年7月~ Journal of Clinical Oncology Reviewer Board
2019年11月~International Journal of Urology Editorial Board
2020年2月~International Journal of Clinical Oncology Deputy Editor
職歴 2019.11.1- 現在  :三重大学大学院医学系研究科 腎泌尿器外科 教授
2016.12.1- 2019.10.31:京都大学大学院医学研究科泌尿器科 准教授
2013.9.1- 2014.12.31  :京都大学医学部附属病院泌尿器科病棟医長
2013.4.1- 2016:11.30 :京都大学大学院医学研究科泌尿器科 講師
2012.4.1- 2013.3.31 :関西医科大学附属枚方病院腎泌尿器外科 助教
2008.4.1- 2012.3.31 : 京都大学大学院医学研究科泌尿器科 助教
2006. 4.17-2008.3.31: ジョンズ ホプキンス大学医学部 泌尿器科研究員
2001.4.1-2002.3.30: 京都大学医学部附属病院 医員
1999.4.1-2001.3.30: 愛知県がんセンター病院 レジデント
1997.4.1-1999.3.30: 国立姫路病院 レジデント
1995.4.1-1997.3.30: 国立姫路病院 研修医
学術(芸術)賞  2003年度 公益財団法人安田記念医学財団 安田癌奨学金受賞(コレステロール生合成系新規酵素遺伝子DHCR24/Seladin-1の前立腺癌における発現、機能解析)
 2005年度 公益財団法人 前立腺研究財団 研究助成 優秀課題 (アンドロゲン不応性メカニズムに関与するシグナル伝達経路の解析)
 2006.2.25 第15回泌尿器分子細胞研究会 研究奨励賞 口演部門
 2010年度 公益財団法人 武田科学振興財団 医学系研究奨励金受賞(新規xenograftモデルを用いた新たな前立腺癌バイオマーカーの探索)
 2013.10.25 第51回日本癌治療学会 優秀演題賞
専門分野 泌尿器科腫瘍・前立腺癌・腹腔鏡手術・ロボット支援下手術・尿路変向/再建術
現在の研究課題 前立腺癌去勢抵抗性変異獲得メカニズムの解明
膀胱癌薬剤耐性機序の解明
担当科目 泌尿器科
主な業績等 (邦文)
1. 後藤 崇之 , 澤田 篤郎 , 小林 恭 , 山﨑 俊成 , 小川 修 , 井上 貴博 ロボット支援下膀胱全摘術後の腔内回腸導管造設術の標準化 日本内視鏡外科学会雑誌 25 140-147
2. 根来宏光、山﨑俊成、小林 恭、松井喜之、小川 修、井上貴博 腹腔鏡下ドナー腎採取術における血管切離時の腎バッグ収納の有用性 日本内視鏡外科学会雑誌 23 127-130, 2018
3. 奥村悦久, 赤松秀輔, 岡田能幸, 根来宏光, 小林恭, 寺田直樹, 山崎俊成, 松井喜之, 井上貴博, 神波大己, 小川修 回腸尿管による上部尿路再建術の有用性 泌尿器科紀要 = Acta urologica Japonica, 64(3): 87-94 2018
4. 久保田聖史, 山崎俊成, 寺本祐記, 伊藤克弘, 高田秀明, 曲淵敏博, 澤田篤郎, 赤松秀輔, 根来宏光, 齋藤亮一, 小林恭, 寺田直樹, 井上貴博, 神波大己, 小川修 長期経過観察で診断しえた転移・再発を有する腎Mucinous Tubular and Spindle Cell Carcinoma(MTSCC)の2例 泌尿器科紀要 = Acta urologica Japonica, 64(3): 111-115 2018
5. 髙田秀明, 小林恭, 小川晃平, 宮田仁美, 澤田篤郎, 赤松秀輔, 根来宏光, 齊藤亮一, 寺田直樹, 山崎俊成, 井上貴博, 寺本祐記, 渋谷信介, 羽賀博典, 海道利実, 上本伸二, 小川修 脳死肝腎同時移植により救命しえた生体肝移植後グラフト肝不全・腎不全の1例 泌尿器科紀要 = Acta urologica Japonica, 63(8): 313-318 2017
6. 伊藤克弘, 根来宏光, 久保田聖史, 高田秀明, 曲渕敏博, 澤田篤郎, 赤松秀輔, 小林恭, 寺田直樹, 山﨑俊成, 井上貴博, 神波大己, 寺本祐記, 小川修 腎甲状腺様濾胞癌の1例 泌尿器科紀要 = Acta urologica Japonica, 63(4): 145-149 2017
7. 小池修平、小林 恭、岡田能幸、渋谷信介、坂井 薫、田中友加里、赤松秀輔、根来宏光、寺田直樹、山崎俊成、松井喜之、井上貴博、神波大己、梅谷由美、海道利実、小川 修  肝移植レシピエントをドナーとした脳死肝移植の1例 泌尿器科紀要 62(10):529-534, 2016
8. 井上貴博 去勢抵抗性前立腺がんと腎臓 腎臓内科・泌尿器科4(2),169-172 2016
9. 後藤崇之、井上貴博、小川 修 高解像度マススペクトロメトリーによる前立腺がん脂質バイオマーカーの探索 腎臓内科・泌尿器科 4(6), 594-598, 2016
10. 井上貴博、小川 修 前立腺癌の基礎研究の現況 日本臨床 74(1): 7-12, 2016
11. 河野有香、寺田直樹、高島 靖、樋上健介、飛田卓哉、後藤修平、砂田琢郎、岡田能幸、柴崎 登、根来宏光、寺田直樹、山崎俊成、松井喜之、井上貴博、神波大己、小川 修 胃利用膀胱拡大術後に発生した進行性膀胱腺癌の1例 泌尿器科紀要 62(1): 33-37 2016
12. 砂田琢郎、小林 恭、柴崎 登、岡田能幸、根来宏光、寺田直樹、山崎俊成、松井喜之、井上貴博、神波大己、小川 修 急速な病勢進行を認めるもカルボプラチン・パクリタクセル投与にて長期寛解が得られている前立腺癌の1例 泌尿器科紀要 61(9): 369-373 2015
13. 砂田琢郎、小林 恭、柴崎 登、岡田能幸、根来宏光、寺田直樹、山崎俊成、松井喜之、井上貴博、神波大己、小川 修 ロボット支援体腔鏡下前立腺全摘除術導入期における骨盤内リンパ節廓清の安全性および妥当性における検討 泌尿器科紀要 61(3): 89-93 2015
14. 濱田彬弘, 山﨑俊成, 根来宏光, 小林恭, 寺田直樹, 杉野善雄, 松井喜之, 井上貴博, 神波大己, 吉村耕治, 小川修 術前アキシチニブが有効であった下大静脈腫瘍塞栓を伴う進行性腎癌の2例 泌尿器科紀要 = Acta urologica Japonica, 60(12): 621-626 2014
15. 水野桂, 井上貴博, 宮崎有, 牧野雄樹, 寺田直樹, 小林恭, 山﨑俊成, 松井喜之, 神波大己, 吉村耕治, 三上芳喜, 小川修 京都大学病院での前立腺全摘術における神経温存適応基準構築に関する検討 泌尿器科紀要 = Acta urologica Japonica, 60(11): 543-547 2014
16. 松井喜之, 兼松明弘, 根来宏光, 小林恭, 寺田直樹, 杉野善雄, 山崎俊成, 井上貴博, 神波大己, 吉村耕治, 小川修 骨盤部放射線照射後症例に対する尿路変向術: 横行結腸導管再訪 泌尿器科紀要 = Acta urologica Japonica, 60(8): 365-370 2014
17. 松本敬優, 小林恭, 村上薫, 大久保和俊, 根来宏光, 寺田直樹, 杉野善雄, 山﨑俊成, 松井喜之, 井上貴博, 神波大己, 吉村耕治, 小川修 導入免疫抑制剤投与により生体腎移植当日に無顆粒球症をきたした慢性腎不全の1例 泌尿器科紀要 = Acta urologica Japonica, 60(6): 275-278 2014
18. 酒谷徹, 清水洋祐, 杉野善雄, 山崎俊成, 今村正明, 松井喜之, 井上貴博, 大久保和俊, 神波大己, 吉村耕治, 小川修 膀胱原発小細胞癌の臨床的検討 泌尿器科紀要 60(5): 221-225 2014
19. 寺田直樹、水野 桂、根来宏光、小林 恭、杉野善雄、山崎俊成、松井喜之、井上貴博、神波大己、吉村耕治、小川 修 開放、腹腔鏡下、ロボット支援前立腺全摘術の手術成績と排尿関連QOLの比較 Japanese Journal of Endourology 27(2): 358-363, 2014
20. 武田将司, 小林恭, 住吉真治, 大久保和俊, 根来宏光, 宮田仁美, 寺田直樹, 杉野善雄, 山﨑俊成, 松井喜之, 井上貴博, 神波大己, 吉村耕治, 小川修 サルコイドーシスを原疾患とする慢性腎不全に対して生体腎移植を施行した1例 泌尿器科紀要 60(7): 319-322 2014
21. 福井智洋, 山﨑俊成, 水野桂, 根来宏光, 小林恭, 寺田直樹, 杉野善雄, 松井喜之, 井上貴博, 神波大己, 吉村耕治, 小川修 腎癌部分切除後に腎周囲脂肪織内晩期再発を認めた1例 泌尿器科紀要60(10): 481-483,2014
22. 井上貴博、小川 修 初期前立腺がんに対する治療 手術?放射線? 腫瘍内科 12 :509-514, 2013
23. 井上貴博、小川 修 外科医が知っておきべき癌治療の薬物療法 前立腺癌の薬物療法 外科 75: 1388-1392, 2013
24. 加藤敬司、井上貴博、溝脇尚志、賀本敏行、神波大己、清水洋祐、則久佳毅、山田知美、平岡眞寛、吉村耕治、小川 修 限局性前立腺癌における根治的放射線外照射治療後の再発に対する救済ホルモン治療の臨床的検討 泌尿器科紀要 58: 599-603, 2012
25. 木村博子, 神波大己, 熱田雄, 牧野雄樹, 大饗政嗣, 松井喜之, 今村正明, 清水洋祐, 井上貴博, 大久保和俊, 吉村耕治, 兼松明弘, 西山博之, 小川修 内視鏡超音波ガイド下経胃的膵仮性嚢胞ドレナージにより治療した腎被膜下嚢胞の1例 泌尿器科紀要, 58(8): 421-424 2012
26. 北 悠希、井上貴博、清水洋祐、神波大己、吉村耕治、小川 修 前立腺癌の術後生化学的再発予測に対するD’Amico高リスク分類の細分類法に関する検討 泌尿器科紀要 58: 319-324, 2012
27. 灰谷崇夫、清水洋祐、井上貴博、大久保和俊、渡部 淳、神波大己、吉村耕治、兼松明弘、西山博之、小川 修 、住吉真治、三上芳喜、錦織桃子 尿管壁全周性肥厚を呈した尿管悪性リンパ腫の1例 泌尿器科紀要 58: 209-213, 2012
28. 後藤崇之、吉村耕治、松井喜之、清水洋祐、井上貴博、大久保和俊、神波大己、西山博之、小川修 尿路上皮癌に対するCisplatin(CDDP)を含む化学療法施行時の腎機能評価方法の比較検討 泌尿器科紀要 57: 671-676,2011
29. 住吉崇幸 , 清水洋祐 , 井上貴博 , 大久保和俊 , 渡部淳 , 神波大己 , 吉村耕治 , 兼松明弘 , 中村英二郎 , 西山博之 , 賀本敏行 , 住吉真治 , 小川修 傍神経節腫を合併した腎細胞癌の1例 泌尿器科紀要57:429-33, 2011.
30. 大饗政嗣 , 大久保和俊 , 植村祐一 , 熱田雄 , 木村博子 , 牧野雄樹 , 松井喜之 , 今村正明 , 清水洋祐 , 井上貴博 , 神波大己 , 吉村耕治 , 兼松明弘 , 西山博之 , 川端大介 , 小川修 多発腎腫瘤を呈したIgG4関連尿細管間質性腎炎の1例 泌尿器科紀要57:309-13,2011
31. 宮﨑有, 神波大己, 清水洋祐, 井上貴博, 大久保和俊, 渡部淳, 吉村耕治, 兼松明弘, 西山博之, 小川修 原発性マクログロブリン血症による尿管アミロイドーシスの1例 泌尿器科紀要57:185-8,2011
32. 後藤 崇之,清水 洋祐,井上 貴博,大久保 和俊,渡部 淳,神波 大己,吉村 耕治,兼松 明弘,西山 博之,小川 修 ホルミニウムレーザーを用い経尿道的に摘除した膀胱傍神経節腫の1例 泌尿器科紀要56:705-7,2010
33. 井上貴博、小川 修. 前立腺癌の発生と進展 分子生物学的アプローチ  臨床検査53巻 1649-1654, 2009
34. 白石裕介, 西山博之, 大久保和俊, 井口亮, 井上貴博, 渡部淳, 神波大己, 吉村耕治, 兼松明弘, 中山貴弘, 畑山博, 小川修 男性不妊を契機に診断された精巣Leydig細胞腫の1例 泌尿器科紀要55:777-81, 2009
35. 白石裕介, 吉村耕治, 井上貴博, 大久保和俊, 渡部淳, 神波大己, 兼松明弘, 中村英二郎, 西山博之, 賀本敏行, 小川修HoLEP術後1年目までの尿失禁・性機能の推移 泌尿器科紀要55:539-43,2009
36. 井上貴博、小川 修. 前立腺癌治療における放射線治療医と泌尿器科医の連携 Urology view vol7 No 6 86-90, 2009
37. 井上貴博、小川 修. 分子標的治療の可能性 Urology view vol7 No2 86-90, 2009
38. 井上貴博. カテーテル管理のなぜ?:泌尿器ケア vol13 1120-1129, 2008
39. 橋村孝幸, 白波瀬敏明, 井上貴博, 山崎俊成, 寺田直樹, 小倉啓司, 荒井陽一, 飛田収一, 上田朋宏 表在性膀胱腫瘍に対するピラルビシンによる術前膀胱内注入療法の検討 泌尿器科紀要51:439-42, 2005
40. 井上貴博、岩村浩志、橋村孝幸 外傷性尿道断裂に対する内視鏡的尿道再建術にて尿管用切除鏡が有用であった1例 泌尿器科紀要44:671-3, 1998
41. 兼松明弘, 井上貴博, 岩村浩志, 高橋毅, 清川岳彦, 中野匡, 筧善行, 日裏勝, 橋村孝幸 80歳以上の超高齢者に対するBCG膀胱内注入療法の検討 泌尿器科紀要44:253-7, 1998
42. 兼松明弘, 井上貴博, 中野匡, 清川岳彦, 筧善行, 日裏勝, 橋村孝幸 進行腎細胞癌患者に対するインターフェロンalpha連日筋注と経口フルオロウラシル剤併用療法  日本泌尿器科学会雑誌89:421-5, 1998
43. 井上貴博、岩村浩志、兼松明弘、筧 善行、橋村孝幸 組織プラスミノーゲンアクチベーターを用いて選択的動脈線溶療法を施行した腎動脈塞栓症の2例 43: 655-659, 1997
44. 井上貴博、兼松明弘、日裏 勝、橋村孝幸、桂 栄考 国立姫路病院における陰茎癌の4例 国立姫路病院紀要 5:11-15, 1997
(英文)
1) Kobayashi T, Terada N, Kimura T, Matsubara N, Murakami K, Mori K, Fujimoto Y, Akamatsu S, Inoue T, Ogawa O. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. Clin Genitourin Cancer. 2020 Feb;18(1):e46-e54. doi: 10.1016/j.clgc.2019.09.011. Epub 2019 Sep 26.
2) Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol. 2019 Dec 9. doi: 10.1007/s10147-019-01596-7. [Epub ahead of print]
3) Yokomizo A, Wakabayashi M, Satoh T, Hashine K, Inoue T, Fujimoto K, Egawa S, Habuchi T, Kawashima K, Ishizuka O, Shinohara N, Sugimoto M, Yoshino Y, Nihei K, Fukuda H, Tobisu KI, Kakehi Y, Naito S; JCOG0401 Investigators. Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†. Eur Urol. 2019 Dec 19. pii: S0302-2838(19)30896-6. doi: 10.1016/j.eururo.2019.11.023. [Epub ahead of print]
4) Kanno, Toru; INOUE, Takahiro; Ito, Katsuhiro; OKUMURA, Kazuhiro; yamada, Hitoshi; KAWAKITA, Mutsushi; Fujii, Masato; Shimizu, Yousuke; Yatsuda, Junji; Moroi, Seiji; SHICHIRI, Yasumasa; AKAO, Toshiya; Sawada, Aturo; Kobayashi, Takashi; OGAWA, Osamu Oncological outcomes and recurrence patterns following laparoscopic radical cystectomy for bladder cancer: A Japanese multicenter cohort 2019 Int J Urol in press
5) Inoue T, Kaneko T, Muramatsu S, Kimura H, Yoshino T, Goto T, Sawada A, Akamatsu S, Kobayashi T, Yamasaki T, Kaya T, Ogawa O LacdiNAc-glycosylated Prostate-Specific Antigen density is a potential biomarker of prostate cancer 2019 Clin Genitourin Cancer. S1558-7673(19)30315-5.
6) Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, Ogawa O, Narita S, Habuchi T, Yamashita S, Mitsuzuka K, Arai Y, Kandori S, Kojima T, Nishiyama H, Kawamura Y, Shimizu Y, Terachi T, Sugi M, Kinoshita H, Matsuda T, Yamada Y, Yamamoto S, Hirama H, Sugimoto M, Kakehi Y, Sakurai T, Tsuchiya N. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. 2019 BMC Cancer. doi: 10.1186/s12885-019-5342-9.
7) Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer. Clin Genitourin Cancer e923-e929. 2019 doi: 10.1016/j.clgc.2019.04.017.
8) Murakami K, Hamada A, Teramoto Y, Matsumoto K, Kita Y, Saito R, Yamasaki T, Matsui Y, Inoue T, Ogawa O, Kobayashi T. Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice. Clin Genitourin Cancer. 2019 e1003-e1010. doi: 10.1016/j.clgc.2019.05.028.
9) Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, Terada N, Kobayashi T, Yamasaki T, Inoue T, Tsuchiya N, Ohyama C, Arai Y, Habuchi T, Morita S, Ogawa O. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol. 2019 May;2(3):320-328.
10) Saga T, Nakamoto Y, Ishimori T, Inoue T, Shimizu Y, Kimura H, Akamatsu S, Goto T, Watanabe H, Kitaguchi K, Watanabe M, Ono M, Saji H, Ogawa O, Togashi K. Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. Cancer Sci. 2019 Feb;110(2):742-750. doi: 10.1111/cas.13911. Epub 2019 Jan 4.
11) Mizuno K, Akamatsu S, Sumiyoshi T, Wong JH, Fujita M, Maejima K, Nakano K, Ono A, Aikata H, Ueno M, Hayami S, Yamaue H, Chayama K, Inoue T, Ogawa O, Nakagawa H, Fujimoto A. eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA. Sci Rep. 2019doi: 10.1038/s41598-019-51459-4.
12) Kanno T, Ito K, Sawada A, Saito R, Kobayashi T, Yamada H, Inoue T, Ogawa O. Complications and reoperations after laparoscopic radical cystectomy in a Japanese multicenter cohort. Int J Urol. 2019 Apr;26(4):493-498. doi: 10.1111/iju.13917. Epub 2019 Feb 1.
13) Kita Y, Hamada A, Saito R, Teramoto Y, Tanaka R, Takano K, Nakayama K, Murakami K, Matsumoto K, Akamatsu S, Yamasaki T, Inoue T, Tabata Y, Okuno Y, Ogawa O, Kobayashi T. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. Br J Cancer.2019 doi: 10.1038/s41416-019-0609-0.
14) Li X, Nakayama K, Goto T, Akamatsu S, Shimizu K, Ogawa O, Inoue T. Comparative evaluation of the extraction and analysis of urinary phospholipids and lysophospholipids using MALDI-TOF/MS.Chem Phys Lipids.2019 doi: 10.1016/j.chemphyslip.2019.104787.
15) Ito K, Kanno T, Sawada A, Saito R, Kobayashi T, Yamada H, Inoue T, Ogawa O. Laparoscopic radical cystectomy in octogenarians: analysis of a Japanese multicenter cohort.2019 Int J Clin Oncol. 1081-1088
16) Goto T, Inoue T, Kobayashi T, Yamasaki T, Ishitoya S, Segawa T, Ito N, Shichiri Y, Okumura K, Okuno H, Kawakita M, Kanaoka T, Terada N, Mukai S, Sugi M, Kinoshita H, Kamoto T, Matsuda T, Ogawa O. Feasibility of laparoscopic adrenalectomy for metastatic adrenal tumors in selected patients: a retrospective multicenter study of Japanese populations. 2019 Int J Clin Oncol. doi: 10.1007/s10147-019-01533-8.
17) Li X, Nakayama K, Goto T, Akamatsu S, Shimizu K, Ogawa O, Inoue T. Data processing on a comparative evaluation of the extraction and analysis procedures for urinary phospholipid and lysophospholipid using MALDI-TOF/MS. 2019 Data Brief. doi: 10.1016/j.dib.2019
18) Uegaki M, Kita Y, Shirakawa R, Teramoto Y, Kamiyama Y, Saito R, Yoshikawa T, Sakamoto H, Goto T, Akamatsu S, Yamasaki T, Inoue T, Suzuki A, Horiuchi H, Ogawa O, Kobayashi T. Downregulation of RalGTPase-activating protein promotes invasion of prostatic epithelial cells and progression from intraepithelial neoplasia to cancer during prostate carcinogenesis. Carcinogenesis. 2019 doi: 10.1093/carcin/bgz082.
19) Ito K, Furuta A, Kido A, Teramoto Y, Akamatsu S, Terada N, Yamasaki T, Inoue T, Ogawa O, Kobayashi T. Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Int J Clin Oncol. 2019 Dec 2. doi:10.1007/s10147-019-01587-8. [Epub ahead of print]
20) Miyazaki Y, Teramoto Y, Shibuya S, Goto T, Okasho K, Mizuno K, Uegaki M, Yoshikawa T, Akamatsu S, Kobayashi T, Ogawa O, Inoue T. Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer. J Clin Med. 2019 doi: 10.3390/jcm8050601.
21) Ito K, Okuno T, Sawada A, Sakai K, Kato Y, Muro K, Yanagita M, Teramoto Y, Yamasaki T, Inoue T, Ogawa O, Kobayashi T. Recurrent Aphthous Stomatitis Caused by Cytomegalovirus, Herpes Simplex Virus, and Candida Species in a Kidney Transplant Recipient: A Case Report. Transplant Proc. 2019 993-997
22) Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, Li X, Utsunomiya N, Goto T, Kobayashi T, Terada N, Inoue T, Kamba T, Fujimoto A, Ogawa O, Akamatsu S. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer. 2019 Sci Rep. doi: 10.1038/s41598-019-40719-y.
23) Suzuki R, Goto T, Kohno S, Kita Y, Shimizu H, Kobayashi T, Yamasaki T, Ogawa O, Inoue T. Arteriovenous fistula after robot-assisted laparoscopic IJU Case reports 2019 https://doi.org/10.1002/iju5.12072
24) Negoro H, Inoue T, Imai K, Goto T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Yamasaki T, Ogawa O. Laparoscopic excision of an acquired ureteral diverticulum: A case report. Asian J Endosc Surg. 2018 Oct 24. doi: 10.1111/ases.12663.
25) Kita Y, Goto T, Akamatsu S, Yamasaki T, Inoue T, Ogawa O, Kobayashi T.Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges. Cancers (Basel). 2018 Sep 21;10(10).
26) Nakamura K, Ikeda I, Inokuchi H, Takayama K, Inoue T, Kamba T, Ogawa O, Hiraoka M, Mizowaki T.A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer. J Radiat Res. 2018 Sep 1;59(5):656-663.
27) Ito K, Takashima Y, Akamatsu S, Terada N, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Negoro H. Intravesical prostatic protrusion is not always the same shape: Evaluation by preoperative cystoscopy and outcome in HoLEP. Neurourol Urodyn. 2018 Sep;37(7):2160-2166.
28) Inoue T, Mizowaki T, Kabata D, Shintani A, Terada N, Yamasaki T, Negoro H, Kobayashi T, Nakamura K, Inokuchi H, Ogawa O.Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.Clin Genitourin Cancer. 2018 Apr;16(2):135-141
29) Kobayashi T, Kanao K, Araki M, Terada N, Kobayashi Y, Sawada A, Inoue T, Ebara S, Watanabe T, Kamba T, Sumitomo M, Nasu Y, Ogawa O.Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer.Int J Clin Oncol. 2018 Apr;23(2):347-352
30) Akamatsu S, Inoue T, Ogawa O, Gleave ME.Clinical and molecular features of treatment-related neuroendocrine prostate cancer.Int J Urol. 2018 Apr;25(4):345-351.
31) Aizawa R, Takayama K, Nakamura K, Inoue T, Kobayashi T, Akamatsu S, Yamasaki T, Ogawa O, Mizowaki T.Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer.Int J Clin Oncol. 2018 Mar 19. doi: 10.1007/s10147-018-1265-8. [Epub ahead of print]
32) Nakamura K, Mizowaki T, Inokuchi H, Ikeda I, Inoue T, Kamba T, Ogawa O, Hiraoka M.
Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.Int J Clin Oncol. 2018 Feb;23(1):158-164.
33) Endo S, Hoshi M, Matsunaga T, Inoue T, Ichihara K, Ikari A.Autophagy inhibition enhances anticancer efficacy of artepillin C, a cinnamic acid derivative in Brazilian green propolis.Biochem Biophys Res Commun. 2018 Feb 26;497(1):437-443
34) Fujiwara M, Soda T, Okada T, Kanamaru H, Inoue T, Ogawa O. Bowel perforation by a peritoneal dialysis catheter: report of two cases. BMC Nephrol. 2017 Oct 16;18(1):312. doi: 10.1186/s12882-017-0737-9.
35) Magaribuchi T, Akamatsu S, Kobayashi T, Kawabata H, Yamasaki T, Inoue T, Ogawa O. Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation. Transpl Infect Dis. 2017 Aug 10. doi: 10.1111/tid.12758. [Epub ahead of print]
36) Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017 Aug;9(8):565-573. doi: 10.1177/1758834017719215. Epub 2017 Jul 5. Review.
37) Kubota M, Terada N, Ito K, Takada H, Magaribuchi T, Sawada A, Akamatsu S, Negoro H, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O. A 45,X/46,XY Male with Orchidopexy Diagnosed with Mixed Germ Cell Tumor After 21-year Follow-up. Urol Case Rep. 2017 May 5;13:120-122. doi: 10.1016/j.eucr.2017.04.001. eCollection 2017 Jul.
38) Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES.  Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.  Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346. [Epub ahead of print]
39) Ito K, Kobayashi T, Koyama T, Tsuzuki T, Kamoto T, Okada Y, Inoue T, Ogawa O Left renal mass presenting uncommon pattern of extension in a patient with intestinal malformation. Int Can Conf J 2017 6:88-91.
40) Inoue T, Terada N, Kobayashi T, Ogawa O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol. 2017 May;14(5):267-283. doi: 10.1038/nrurol.2017.19. Epub 2017 Feb 21. Review..
41) Okada Y, Sonoshita M, Kakizaki F, Aoyama N, Itatani Y, Uegaki M, Sakamoto H, Kobayashi T, Inoue T, Kamba T, Suzuki A, Ogawa O, Taketo MM Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.  Cancer Sci. 2017 Apr;108(4):744-752. doi: 10.1111/cas.13187.
42) Mizuno K, Inoue T, Kinoshita H, Yano T, Kawanishi H, Kanda H, Terada N, Kobayashi T, Kamba T, Mikami Y, Shiraishi T, Uemura Y, Imai Y, Honjo G, Shirase T, Okumura K, Kawakita M, Ogura K, Sugimura Y, Matsuda T, Ogawa O. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study. Jpn J Clin Oncol. 2016 Dec;46(12):1156-1161.
43) Terada N, Akamatsu S, Okada Y, Negoro H, Kobayashi T, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol. 2016 Dec;21(6):1155-1161.
44) Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer. Int J Clin Oncol. 2016 Aug;21(4):783-90. doi: 10.1007/s10147-016-0954-4. Epub 2016 Feb 3
45) Kobayashi T, Kamba T, Terada N, Yamasaki T, Inoue T, Ogawa O High incidence of urological complications in men dying from prostate cancer.  Int J Clin Oncol. 2016 Dec;21(6):1150-1154.
46) Kobayashi T, Kimura T, Lee C, Inoue T, Terada N, Kono Y, Kamba T, Kim CS, Egawa S, Ogawa O. Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy.  Jpn J Clin Oncol. 2016 Aug;46(8):762-7. doi: 10.1093/jjco/hyw061.
47) Yoshikawa T, Kobori G, Goto T, Akamatsu S, Terada N, Kobayashi T, Tanaka Y, Jung G, Kamba T, Ogawa O, Inoue T. An original patient-derived xenograft of prostate cancer with cyst formation. Prostate. 2016 Aug;76(11):994-1003. doi: 10.1002/pros.23188. Epub 2016 Apr 21.
48) Fukui T, Matsui Y, Umeoka S, Inoue T, Kamba T, Togashi K, Ogawa O, Kobayashi T. Predictive value of radiological response rate for pathological response to neoadjuvant chemotherapy and post-cystectomy survival of bladder urothelial cancer. Jpn J Clin Oncol. 2016 Mar 8. pii: hyw025. [Epub ahead of print]
49) Mizowaki T, Norihisa Y, Takayama K, Ikeda I, Inokuchi H, Nakamura K, Kamba T, Inoue T, Kamoto T, Ogawa O, Hiraoka M. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer. Int J Clin Oncol. 2016 Feb;21(1):148-55. doi: 10.1007/s10147-015-0867-7. Epub 2015 Jul 4.
50) Takahiro Inoue, Keiji Ogura, Mutushi Kawakita, Hiromasa Tsukino, Shusuke Akamatsu, Toshinari Yamasaki, Yoshiyuki Matsui, Takehiko Segawa, Yoshio Sugino, Toshiyuki Kamoto, Tomomi Kamba, Shiro Tanaka, Osamu Ogawa Effective and safe administration of low-dose estramustine phosphate for castration-resistant prostate cancer. Clin Genitourinary Cancer 2015Feb;14(1):e9-e17. doi: 10.1016/j.clgc.2015.08.008. Epub 2015 Sep 2.
51) Sunada T, Kobayashi T, Furuta A, Shibuya S, Okada Y, Negoro H, Terada N, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O. Large Retroperitoneal Mass Diagnosed as Adrenal Chronic Expanding Hematoma.Urology. 2015 Jul 16. pii: S0090-4295(15)00648-2. doi: 10.1016/j.urology.2015.06.043. [Epub ahead of print]
52) Goto T, Terada N, Inoue T, Kobayashi T, Nakayama K, Okada Y, Yoshikawa T,Miyazaki Y, Uegaki M, Utsunomiya N, Makino Y, Sumiyoshi S, Yamasaki T, Kamba T, Ogawa O. Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.Prostate. 2015 Dec;75(16):1821-30. [Epub ahead of print]
53) Shibasaki N, Yamasaki T, Kanno T, Arakaki R, Sakamoto H, Utsunomiya N, Inoue T, Tsuruyama T, Nakamura E, Ogawa O, Kamba T Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma..PLoS One. 2015 Jun 26;10(6):e0130980. doi: 10.1371/journal.pone.0130980. eCollection 2015.
54) Takahiro Inoue; Hidefumi Kinoshita; Naoki Terada; Takashi Kobayashi; Toshinari Yamasaki; Yoshiyuki Matsui; Tomomi Kamba; Hidekazu Inui; Motohiko Sugi; Tadashi Matsuda; Osamu Ogawa  Evaluation of prognostic factors after radical prostatectomy in pT3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology 2015;doi: 10.1093/jjco/hyv077
55) Nakayama K, Inoue T, Sekiya S, Terada N, Miyazaki Y, Goto T, Kajihara S, Kawabata S, Iwamoto S, Ikawa K, Oosaga J, Tsuji H, Tanaka K, Ogawa O. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer. PLoS One. 2014 Sep 18;9(9):e107234. doi: 10.1371/journal.pone.0107234. eCollection 2014.
56) Maeno A, Terada N, Uegaki M, Goto T, Okada Y, Kobayashi T, Kamba T, Ogawa O, Inoue T. Up-regulation of miR-582-5p regulates cellular proliferation of prostate cancer cells under androgen-deprived conditions. Prostate. 2014 ;74(16):1604-12.
57) Takayuki Goto, Naoki Terada, Takahiro Inoue, Kenji Nakayama, Takeshi Yoshikawa, Yu Miyazaki, Masayuki Uegaki, Yosuke Shimizu, Shinji Sumiyoshi, Takashi Kobayashi, Tomomi Kamba, Koji Yoshimura, Osamu Ogawa The Expression Profile of Phosphatidylinositol in High Spatial Resolution Imaging Mass Spectrometry as A Potential Biomarker for Prostate Cancer. PLoS One 2014 ;9(2):e90242. doi: 10.1371/journal.pone.0090242. eCollection 2014.
58) Ikeda I, Mizowaki T, Norihisa Y, Takayama K, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O, Hiraoka M. Long-term Outcomes of Dynamic Conformal Arc Irradiation Combined with Neoadjuvant Hormonal Therapy in Japanese Patients with T1c-T2N0M0 Prostate Cancer: Case Series Study. Jpn J Clin Oncol. 2013 Dec 29. [Epub ahead of print]
59) Kobayashi T, Inoue T, Kamba T, Ogawa O. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 26;14(8):15615-35. doi: 10.3390/ijms140815615. Review.
60) Inoue T, Kinoshita H, Inui H, Komai Y, Nakagawa M, Oguchi N, Kawa G, Sugi M, Ohe C, Miyasaka C, Nakano Y, Sakaida N, Uemura Y, Matsuda T. Pathological outcomes of Japanese men eligible for active surveillance after radical prostatectomy. Int J Clin Oncol. 2014 19: 379-383
61) Akamatsu S, Takahashi A, Takata R, Kubo M, Inoue T, Morizono T, Tsunoda T, Kamatani N, Haiman CA, Wan P, Chen GK, Le Marchand L, Kolonel LN, Henderson BE, Fujioka T, Habuchi T, Nakamura Y, Ogawa O, Nakagawa H. Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLoS One. 2012;7(10):e46454. doi: 10.1371/journal.pone.0046454. Epub 2012 Oct 10
62) Yamasaki T, Kamba T, Kanno T, Inoue T, Shibasaki N, Arakaki R, Yamada T, Kondo K, Kamoto T, Nishiyama H, Ogawa O, Nakamura E. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy. Cancer Sci. 2012 Nov;103(11):2027-37
63) Kita Y, Shimizu Y, Inoue T, Kamba T, Yoshimura K, Ogawa O. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients. Int J Clin Oncol. 2012 in press
64) Li B, Shimizu Y, Kobayashi T, Terada N, Yoshimura K, Kamba T, Mikami Y, Inoue T, Nishiyama H,Ogawa O. Overexpression of ETS-1 is associated with malignant biological features of prostate cancer. Asian J Androl. 2012 Nov;14(6):860-3.
65) Matsui Y, Nishiyama H, Yoshimura K, Xing ND, Sumiyoshi T, Saito R, Inoue T, Kamba T, Ogawa O. The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers. Int J Clin Oncol. 2012 Mar 13. [Epub ahead of print]
66) Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen GK, Le Marchand L, Kolonel LN, Katoh T, Yamano Y, Yamakado M, Takahashi H, Yamada H, Egawa S, Fujioka T, Henderson BE, Habuchi T, Ogawa O, Nakamura Y, Nakagawa H. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese.
 Nat Genet. 2012 Feb 26. doi: 10.1038/ng.1104. [Epub ahead of print]
67) Takahiro Inoue, Osamu Ogawa "Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer," Prostate Cancer, vol. 2011, Article ID 647987, 7 pages, doi:10.1155/2011/647987. 2011.
68) Kanno T, Kamba T, Yamasaki T, Shibasaki N, Saito R, Terada N, Toda Y, Mikami Y, Inoue T, Kanematsu A, Nishiyama H,Ogawa O, Nakamura E.JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene. 2011 Oct 24. doi: 10.1038/onc.2011.475.
69) Mizowaki T, Takayama K, Norihisa Y, Ogura M, Kamba T, Inoue T, Shimizu Y, Kamoto T, Ogawa O, Hiraoka M.Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer.Int J Clin Oncol. 2012 Dec;17(6):562-8
70) Xing ND, Ding ST, Saito R, Nishizawa K, Kobayashi T, Inoue T, Oishi S, Fujii N, Lv JJ, Ogawa O, Nishiyama H. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-l-cysteine, a novel Eg5 inhibitor. Asian J Androl.13:236-41, 2011
71) Shimizu Y, Hamazaki Y, Hattori M, Doi K, Terada N, Kobayashi T, Toda Y, Yamasaki T, Inoue T, Kajita Y, Maeno A, Kamba T, Mikami Y, Kamoto T, Yamada T, Kanno T, Yoshikawa K, Ogawa O, Minato N, Nakamura E. SPA-1 controls the invasion and metastasis of human prostate cancer. Cancer Sci. 102:828-36, 2011
72) Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, Yamada T, Kamoto T, Ogawa O, Nakamura E.(2010) Activation of Rac1 Is Closely Related to Androgen-Independent Cell Proliferation of Prostate Cancer Cells Both in Vitro and in Vivo. Mol Endocrinol 24 722-34, 2010
73) Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O. Identification of EP4 as a Potential Target for the Treatment of Castration-Resistant Prostate Cancer Using a Novel Xenograft Model. Cancer Res 70: 1606-15, 2010
74) Takashi Kobayashi, Yosuke Shimizu, Naoki Terada, Toshinari Yamasaki, Eijiro Nakamura, Yoshinobu Toda, Hiroyuki Nishiyama, Toshiyuki Kamoto, Osamu Ogawa and Takahiro Inoue  Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate 70:866-874 2010
75) Naoki Terada, Yosuke Shimizu, Toru Yoshida, Atsushi Maeno, Tomomi Kamba, Takahiro Inoue, Eijiro Nakamura, Toshiyuki Kamoto, Osamu Ogawa Antiandrogen Withdrawal Syndrome and Alternative Antiandrogen Therapy Associated with the W741C Mutant Androgen Receptor in a Novel Prostate Cancer Xenograft. Prostate 70:252-261, 2009 
76) Kobayashi T, Nakamura E, Shimizu Y, Terada N, Maeno A, Kobori G, Kamba T, Kamoto T, Ogawa O, Inoue T.  Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells. Biochem Biophys Res Commun. 387(1):196-201, 2009
77) Zeng Y, Kulkarni P, Inoue T, Getzenberg RH. Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem 107: 179-88, 2009
78) Inoue T, Maeno A, Talbot C Jr, Zeng Y, Yeater DB, Leman ES, Kulkarni P, Ogawa O, Getzenberg RH.  Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells. Prostate 69: 861-73, 2009 
79) Inoue T, Leman ES, Yeater DB, Getzenberg RH. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate 68: 1048-1056, 2008
80) Takahiro Inoue, Takashi Kobayashi, Naoki Terada, Yosuke Shimizu, Toshiyuki Kamoto, Osamu Ogawa and Eijiro Nakamura Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology & Metabolism Vol. 2, No. 5,689-704, 2007
81) Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Terada N, Kobayashi T, Kinoshita H, Kamoto T, Nakamura E, Ogawa O.Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int. 100:685-90, 2007
82) Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E, Ogawa O. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol Endocrinol 20 3053-69, 2006
83) Takahiro Inoue, Takehiko Segawa, Taizou Shiraishi, Tomomi Yamada, Naoko Kinukawa, Toru Yoshida, Yoshinobu Toda, Yosuke Shimizu, Eijiro Nakamura, Hidefumi Kinoshita, Toshiyuki Kamoto, Osamu Ogawa. High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase. BJU Int. 98 197-200, 2006
84) Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nose V, Kaelin WG Jr. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 168 574-84, 2006
85) Toru Yoshida, Hidefumi Kinoshita, Takehiko Segawa, Eijiro Nakamura, Takahiro Inoue, Yosuke Shimizu, Toshiyuki Kamoto, Osamu Ogawa. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65 9611-6, 2005
86) Takahiro Inoue, Takehiko Segawa, Taizou Shiraishi, Toru Yoshida, Yoshinobu Toda, Tomomi Yamada, Naoko Kinukawa, Hidefumi Kinoshita, Toshiyuki Kamoto, Osamu Ogawa. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 66 332-337, 2005
87) Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Hayashi N, Inoue T, Sugimura Y, Nishiyama N, Fujita T, Chao J, Ushijima T, Shirai TDown-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate. 54(3):187-93, 2003
88) Takahiro Inoue, Takuichi Hioki, Norio Hayashi, Satoru Takahashi, Tomoyuki Shirai, Yoshiki Sugimura: Preoperative predictors of cancerous involvement of the neurovascular bundles in patients with localized prostate cancer; Int J Urol 9 47-53, 2002
89) Takahiro Inoue, Takuichi Hioki, Yasukaki Arai,Yoshitaka Inaba, Yoshiki Sugimura: Ureteroarterial fistula controlled by intraluminal ureteral occlusion ;Int J Urol 9 120-121, 2002
90) S Takahashi, S Suzuki, S Inaguma,Y-M Cho , Y Ikeda, N Hayashi, T Inoue, Yoshiki Sugimura, N Nishiyama, T Fujita,T Ushijima, Tomoyuki Shirai : Down-regultion of Lsm1 is involved in human prostate cancer progression:Br J Cancer 86 940-946, 2002
91) Satoru Takahashi, Shugo Suzuki, Shingo Inaguma, Yoshihisa Ikeda, Young-Man Cho, Naoki Nishiyama, Tamio Fujita, Takahiro Inoue, Takuichi Hioki, Yoshiki Sugimura, Toshikazu Ushijima, Tomoyuki Shirai: Down-regulation of human X-box binding protein 1(hXBP-1) expression correlates with tumor progression in human prostate cancers; Prostate 50 154-161, 2002
92) Kazuhiro Iguchi, Shigeyuki Usui, Takahiro Inoue, Yoshiki Sugimura, Masae Tatematsu, Kazuyuki Hirano: High-level expression of zinc transpoter-2 in the rat lateral and dorsal prostate ;J Andrology 23 819-824, 2002
93) Takahiro Inoue, Hayao Nakanishi, Ken-Ichi Inada, Takuichi Hioki, Masae Tatematsu, Yoshiki Sugimura : Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells ; J Urology 166 2134-2141, 2001
94) Yoshiki Sugimura, Takuichi Hioki, Yasyshi Yamada, Miki Fumino, Takahiro Inoue. An anterior urethral stitch improves urinary incontinence following radical prostatectomy ;Int J Urol 8 153-157, 2001
95) Takahiro Inoue, Takayuki Hashimura: Spontaneous regression of a renal arteriovenous malformation; J Urology,163 232-233, 2000
96) Inoue T, Hashimura T, Iwamura H, Takahashi T, Segawa T, Kakehi Y, Nakano T, Hiura M, Kanematsu A, Katsura Y, Katsura Y. Multivariate analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo. 46:229-34, 2000
97) Inoue T, Kanematsu A, Hashimura T. Geriatric ureteropelvic junction obstruction: the possible role of an arteriosclerotic lower pole branch of renal artery: report of two cases. Hinyokika Kiyo. 46:123-6, 2000
98) Takahiro Inoue,Akito Terai,Toshiro Terachi,Takahito Souma, Osamu Yoshida: Synchronous Testicular Seminoma and Adrenocortical Carcinoma: A Case Report ; Int J Urol 5 : 615-617, 1998
99) Terai A, Terachi T, Inoue T, Ogawa O, Kakehi Y, Okada Y, Yoshida O. Laparoscopic adrenalectomy for bilateral pheochromocytoma: a case report. Int J Urol. 4:300-3, 1997
100) Lin, Z., Yamasaki, S., Kurazono, H., Ohmura, M., Karasawa, T., Inoue, T., Sakamoto, S., Suganami, T., Takeoka, T., Taniguchi, Y. and Takeda, Y. (1993), Cloning and Sequencing of Two New Verotoxin 2 Variant Genes of Escherichia coli Isolated from Cases of Human and Bovine Diarrhea. Microbiology and Immunology, 37: 451–459.
(書籍)
1) 井上貴博 経皮的腎瘻造設術 エンドウロロジー Urologic Surgery Next. 3 62-69 2018 Medical View
2) Inoue T. Patient-derived Xenografts for Research on Hormonal Therapy of Prostate Cancer Chapter4 19-30: Hormonal Therapy and Castration Resistance of Prostate Cancer Springer 2018
3) Inoue T. Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer Chapter 26 249-256: Hormonal Therapy and Castration Resistance of Prostate Cancer Springer 2018
4) 乾 秀和、井上貴博、川端和史、木下秀文、松田公志 腹腔鏡下腎部分切除術 Year Book of RCC 2012 71-79 (メディカルレビュー社)
5) 井上貴博 新前立腺癌学 最新の基礎研究と診断・治療 前立腺癌の治療 放射線療法 外照射療法 再発後の治療戦略 74 (増刊 3) 525-529, 2016
6) 井上貴博. アンドロゲン非依存性進展に伴うシグナル伝達異常: 日本臨床 前立腺癌 第2版(増刊号5) 69巻 121-125, 2011
7) 井上貴博、小川 修ホルモン不応性前立腺癌の化学療法 :Annual Review 腎臓 (中外医学社) 226-231, 2009
8) 井上貴博、小川 修 その他の新しい治療法 :インフォームドコンセントのための図説シリーズ (医薬ジャーナル、大園誠一郎、荒井陽一 編)前立がん 14.122-125、2008